Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History AMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics AMGN

Champion - 10+ consecutive years of dividend increases

Max Ratio

7.98

5Y Dividend Growth

55.00 %

Consecutive Years

13 years

5Y Average Payout Ratio

74.36 %
Forward Annual Dividend Yield 3.17 %
Consecutive Years 13
Forward Annual Dividend 9.52 USD
Consistent Years 13
Dividend CAGR 3Y 8.53 %
Continuous Dividends
Dividend CAGR 5Y 9.18 %
Payout Ratio TTM 44.61 %
Dividend CAGR 10Y 13.94 %
Ex Dividend Date 16.05.2025

Amgen Inc

AMGN
Current price
300.37 USD +4.18 USD (+1.41%)
Last closed 297.00 USD
ISIN US0311621009
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 159 698 845 696 USD
Yield for 12 month -7.60 %
1Y
3Y
5Y
10Y
15Y
AMGN
21.11.2021 - 28.11.2021

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

314.27 USD

P/E Ratio

27.10

Dividend Yield

3.17 %

Financials AMGN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures AMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+33 424 000 000 USD

Last Year

+28 190 000 000 USD

Current Quarter

+8 149 000 000 USD

Last Quarter

+9 086 000 000 USD

Current Year

+20 566 000 000 USD

Last Year

+19 739 000 000 USD

Current Quarter

+5 181 000 000 USD

Last Quarter

+5 974 000 000 USD
EBITDA 15 726 000 128 USD
Operating Margin TTM 28.73 %
Price to Earnings 27.10
Return On Assets TTM 7.04 %
PEG Ratio 0.99
Return On Equity TTM 105.67 %
Wall Street Target Price 314.27 USD
Revenue TTM 34 126 000 128 USD
Book Value 11.54 USD
Revenue Per Share TTM
Dividend Share 9.13 USD
Quarterly Revenue Growth YOY 9.40 %
Dividend Yield 3.17 %
Gross Profit TTM 23 569 999 872 USD
Earnings per share 10.94 USD
Diluted Eps TTM 10.94 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -18.70 %
Profit Margin 17.39 %

Stock Valuation AMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 27.10
Forward PE 14.20
Enterprise Value Revenue 6.10
Price Sales TTM 4.68
Enterprise Value EBITDA 13.61
Price Book MRQ 25.69

Technical Indicators AMGN

For 52 Weeks

249.07 USD 336.01 USD
50 Day MA 283.03 USD
Shares Short Prior Month 12 938 502
200 Day MA 293.30 USD
Short Ratio 4.94
Shares Short 13 271 690
Short Percent 2.48 %